PharmedOut's Letter to the FDA on label changes and advisory committee meetings
January 19, 2021 Family medicine residents don’t interact with pharma as much as they once did By Ed Silverman
February 27, 2020 Health care conference about conflicts of interest has a conflict itself, say critics who won’t attend By Ed Silverman
June 11, 2019 Industry-funded attacks on the CDC's opioid prescribing guideline are eroding public health By Ben Goodwin, Judy Butler, and Adriane Fugh-Berman
May 30, 2019: The chronic-pain quandary: Amid a reckoning over opioids, a doctor crusades for caution in cutting back By Andrew Joseph
April 9, 2019: ‘We owe much to the Sackler family’: How gifts to a top medical school advanced the interests of Purdue Pharma By Andrew Joseph
October 11, 2018: Pfizer pays $700,000 to settle charges over misleading copay coupons By Ed Silverman
October 2, 2018: Caregivers or Marketers? Nurses paid by drug companies facing scrutiny as whistleblower lawsuits mount By Ed Silverman and Karen Weintraub
June 18, 2018: Donations of $4,500 overdose antidote were PR gold for drug maker — but some kits were close to expiring By Max Blau
April 23, 2018: How a patient advocacy group is used to promote an Insys drug and other fentanyl meds By Ed Silverman
March 9, 2018: McCaskill plans a bill to force pharma to disclose payments to nonprofits and advocacy groups By Ed Silverman
June 28, 2017: The FDA may move to shorten that grim list of side effects in every drug ad. Advertising execs can’t wait By Megan Thielking
September 30, 2016: A potent painkiller, and the drug maker's marketing, are faulted in a woman's death By David Armstrong
July 6, 2016: Pfizer agrees to opioid marketing deal to escape a lawsuit by Chicago By Ed Silverman